BOULDER, Colo.--(BUSINESS WIRE)--Biodesix announced today that Humana, Medical Mutual of Ohio and
PreferredOne health plans have established reimbursement coverage of the VeriStrat® test, Biodesix’
proteomic blood test for patients with non-small cell lung cancer
(NSCLC). VeriStrat has received positive coverage decisions from Humana,
Medical Mutual of Ohio, and PreferredOne and as a result of these
coverage changes, an additional 11.5 million Americans now have
insurance coverage for VeriStrat.
testing and Genetic Counseling General Policy”
VeriStrat results provide physicians with prognostic and predictive
information to inform treatment of advanced NSCLC, and can facilitate
patient-physician conversations about prognosis, life expectancy, and
treatment recommendations. The test is clinically proven for use in
patients with advanced NSCLC and has been recommended as such in the
standard of care guidelines since late 2014. VeriStrat is often used by
physicians as part of the Biodesix Lung Reflex™ testing strategy, which
combines genomic mutation testing and proteomic testing to provide more
complete information on tumor mutation status as well as the patient’s
immune response to the tumor.
Based on published clinical data, Humana, Medical Mutual of Ohio and
PreferredOne independently determined and published policy stating that
VeriStrat can be considered medically necessary for patients with
Humana, Inc. (NYSE: HUM) is a national provider of healthcare, with
9.6 million enrolled members according to their website. Humana’s
policy, “Pharmacogenomics and Companion Diagnostics” is
effective as of 8/25/16 and can be accessed at: http://dctm.humana.com/Mentor/Web/v.aspx?chronicleID=0900092981a619a0&
Medical Mutual, a privately owned, not-for-profit, member-owned mutual
company with 1.6 million enrolled members, is the oldest and largest
health insurance company headquartered in Ohio. The company’s policy, “Genetic
testing and Genetic Counseling General Policy” is effective as of
10/14/2016, and can be accessed at: https://provider.medmutual.com/TOOLS_and_RESOURCES/Care_Management/MedPolicies/PDF/201303
PreferredOne is a privately owned company with 285,000 members in the
state of Minnesota. The company’s policy, “Molecular Testing:
Tumor/Neoplasm Biomarkers,” is effective as of 9/13/2016 and can
be accessed at: https://www.preferredone.com/shared/medicalpolicy/medicalpolicyactive/mp_m001.pdf
VeriStrat and Biodesix are registered trademarks of Biodesix, Inc.
All other trademarks referenced herein are the property of their
Biodesix® is a molecular diagnostics company advancing the
development of innovative blood tests in oncology to enable precision
medicine. Biodesix discovers, develops and commercializes multivariate
protein and genomic diagnostic blood tests, including the GeneStrat®
and VeriStrat® tests that deliver results within 72 hours.
The company is changing the standard of care by providing physicians
with diagnostic tests for better therapeutic guidance, more accurate
prognosis and enhanced disease monitoring to improve patient outcomes.
At the forefront of precision medicine, Biodesix is developing new blood
tests to identify patients who may benefit from immunotherapies. In
addition to developing novel diagnostics independently, the company
partners with biotechnology and pharmaceutical companies to develop
companion diagnostics for use with therapeutic agents.